1. Update on current practice in laboratory medicine in respect of natriuretic peptide testing for heart failure diagnosis and management in Europe. The CARdiac MArker guideline Uptake in Europe (CARMAGUE) study.
- Author
-
UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service de biochimie médicale, Hammerer-Lercher, Angelika, Gruson, Damien, Stankovic, Sanja, Collinson, Paul, Suvisaari, Janne, Pulkki, Kari, Duff, Christopher J, Baum, Hannsjörg, Stavljenic-Rukavina, Ana, Aakre, Kristin M, Langlois, Michel R, Laitinen, Paivi, EFLM Task Group Cardiac Markers, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service de biochimie médicale, Hammerer-Lercher, Angelika, Gruson, Damien, Stankovic, Sanja, Collinson, Paul, Suvisaari, Janne, Pulkki, Kari, Duff, Christopher J, Baum, Hannsjörg, Stavljenic-Rukavina, Ana, Aakre, Kristin M, Langlois, Michel R, Laitinen, Paivi, and EFLM Task Group Cardiac Markers
- Abstract
BACKGROUND: The European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) initiated the CArdiac MARker Guidelines Uptake in Europe (CAMARGUE) Study to survey if current biomarker testing for heart failure (HF) in Europe is in accordance with up-dated guidelines. METHODS: A web-based questionnaire was distributed to clinical laboratories via European biochemical societies in 2019. Questions covered the type of natriuretic peptide (NP) assays performed, decision limits for HF, and opinion concerning requirement of different thresholds in patients with renal failure or obesity. RESULTS: There were 347 participating laboratories mostly from European countries with 266 offering NP testing. NP testing was increased from 67% to 77% between 2013 and 2019. NT-proBNP remained the preferred biomarker. Recommended decision limits were implemented for BNP (85%) and better focused for NT-proBNP (40%) than in the previous survey. The survey revealed that laboratorians are willing to support the translation of adjusted cut-off values for age, gender and for patients with conditions like renal insufficiency. CONCLUSION: Guidelines stimulate clinical laboratories to offer NP testing with high value for the diagnosis and management of HF, and to present adjusted medical decision limits. Future guidelines should encourage the use of personalized cut-offs for some confounding factors.
- Published
- 2020